When it comes to preventing malaria, researchers and public health officials have been hopeful about the potential of a monoclonal antibody, one injection of which could provide recipients with several months of protection against the parasite. Such a tool, experts have thought, could give babies a layer of defense even before they start receiving doses of the malaria vaccines that have rolled out in recent years. New research detailed Thursday has cast doubt on that strategy. Scientists tested the monoclonal, known as L9LS, in infants in Mali, finding that it was 78% effective versus a placebo in providing protection against the malaria parasite over the six-month transmission season, similar to what has been seen in studies of the antibody in older kids and adults. However, they also reported that it interfered with the immune response the malaria vaccine R21 elicits, resulting in a 20% to 30% drop in antibody levels generated by the immunization, according to an abstract presented at the annual meeting of the American Society of Tropical Medicine and Hygiene. While it’s not clear what the diminished immune responses seen in blood tests would mean for the real-world protection offered by the vaccine, researchers say they’re going to focus on groups other than babies as they plan the pivotal studies that could lead to L9LS being approved, which they hope to start in 2028. “We have these other clear use cases, so let’s get those done and get it approved and we can come back and revisit this,” said Robert Seder of the National Institute of Allergy and Infectious Diseases, whose lab helped develop L9LS. There is no panacea against malaria, and various strategies come with advantages and disadvantages that public health officials have to weigh as they think about which approach to prioritize and for whom, particularly given the limited funding for a disease that predominantly affects poor countries. The infection killed about 610,000 people in 2024, the majority of them children under 5 years old in sub-Saharan Africa. R21 and RTS,S, the two malaria vaccines, are seen as major scientific breakthroughs — they are the first vaccines against any parasite — but they require multiple doses to be effective, the first of which comes at 5 months of age. They do, however, provide some level of protection for years. A monoclonal, on the other hand, can provide several months of protection with just one dose, which could be enough to cover recipients for peak transmission periods. (In areas with year-round transmission, deploying antibodies might require two to three doses a year, experts say.) It could offer an alternative to the current strategy of giving children existing antimalarial treatments every month during high-transmission periods, which is a cheap and effective preventive strategy but that opens the door to adherence challenges. “A monoclonal antibody, with only one shot, provides an efficacy over six months, and those six months correspond to the season of malaria in Sahelian regions,” said Kassoum Kayentao of Mali’s University of Sciences, Techniques, and Technologies of Bamako, one of the experts involved with the new research. “In terms of logistics, in terms of programmatical use, this could be a very good tool.” The constraint with antibodies is that they are comparatively costly, though there are efforts underway to bring down the price of each dose as researchers head to pivotal trials. The new study enrolled infants from 1 month to 12 months, gave them either a placebo or the L9LS monoclonal, and then doses of the R21 vaccine. That sequence was what created the issue, researchers said. The malaria vaccines work by training the immune system to recognize a protein on the parasite known as the circumsporozoite protein, or CSP. The monoclonal L9LS also binds to the CSP. That meant that, when the infants who had been given L9LS later received R21, the antibody bound to the vaccine as well, essentially interfering with the full immune response it was meant to trigger, researchers believe. Experts said there were still key groups of people who could benefit from a monoclonal and who could be the focus of future studies. Among them are pregnant people, as an infection during pregnancy can be dangerous for both parent and baby. Kids who are hospitalized with malaria are another target group. In the months after they’re released from hospital and as they recover from the infection-caused anemia, they are particularly vulnerable to severe outcomes from another malaria case. The current strategy of what’s called post-discharge malaria chemoprevention involves taking available preventive drugs every month, whereas one shot of a monoclonal as they leave the hospital could cover them for months. André-Marie Tchouatieu of the Medicines for Malaria Venture, who was not involved in the study, said that, despite the issue seen with L9LS and the vaccine, it did not limit the potential impact the monoclonal and next-generation versions could have in reducing the burden of malaria broadly. “Definitely there will be a use case,” said Tchouatieu, who this month co-authored a New England Journal of Medicine review outlining the advantages and challenges of different malaria strategies. “Every tool that can prove efficacy and safety will have a role to play in the whole strategy for malaria elimination.”
Study raises doubts about combining vaccine, monoclonal antibody to protect against malaria
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.